These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma. Peter HH; Deutschmann EM; Schultheis W; Deicher H Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106 [TBL] [Abstract][Full Text] [Related]
8. Adjuvant immunotherapy in melanoma with irradiated autologous tumor cells and low dose cyclophosphamide. Elias EG; Suter CM; Fabian DS J Surg Oncol; 1997 Jan; 64(1):17-22. PubMed ID: 9040795 [TBL] [Abstract][Full Text] [Related]
9. BCG immunotherapy of malignant melanoma: summary of a seven-year experience. Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271 [TBL] [Abstract][Full Text] [Related]
10. [Melanoma therapy]. Kleeberg UR Dtsch Med Wochenschr; 1976 Jun; 101(23):904-8. PubMed ID: 773624 [No Abstract] [Full Text] [Related]
11. The use of oral BCG in the treatment or metastatic malignant melanoma. Pritchard KI; Cowan DH; Baker MA; Osoba D; Phillips RA; Clark DA Med Pediatr Oncol; 1976; 2(2):173-81. PubMed ID: 785199 [TBL] [Abstract][Full Text] [Related]
12. Eradication of microscopic lymph nodes metastases after injection of living BCG adjacent to the primary tumor. Smith HG; Bast RC; Zbar B; Rapp HJ J Natl Cancer Inst; 1975 Dec; 55(6):1345-52. PubMed ID: 1107574 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma. Abdi EA; Hanson J; McPherson TA Am J Clin Oncol; 1987 Apr; 10(2):117-22. PubMed ID: 3565312 [TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant melanoma by intratumoral injection of BCG. Pinsky CM; Hirshaut Y; Oettgen HF Natl Cancer Inst Monogr; 1973 Dec; 39():225-8. PubMed ID: 4595322 [No Abstract] [Full Text] [Related]
15. Adjuvant BCG immunotherapy for malignant melanoma. Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591 [TBL] [Abstract][Full Text] [Related]
16. Monitoring immunotherapy with Bacillus Calmette-Guérin by antibody titer. Wile AG; Sparks FC; Morton DL Cancer Res; 1977 Jul; 37(7 Pt 1):2251-6. PubMed ID: 324610 [TBL] [Abstract][Full Text] [Related]
17. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma. Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970 [TBL] [Abstract][Full Text] [Related]
18. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case. Coates AS; Peters M Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705 [TBL] [Abstract][Full Text] [Related]
19. Adjuvant immunotherapy in melanoma: a new approach. Elias EG; Tomazic VJ; Buda BS J Surg Oncol; 1992 Jul; 50(3):144-8. PubMed ID: 1619935 [TBL] [Abstract][Full Text] [Related]
20. Results of adjuvant BCG immunotherapy in malignant melanoma. Wätzig V; Knopf B Arch Geschwulstforsch; 1981; 51(6):493-6. PubMed ID: 7332442 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]